Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Ibritumomab
See also Monoclonal antibodies
General information
Ibritumomab is a murine IgG 1 anti-CD20 antibody, the parent of the engineered chimeric antibody rituximab, a monoclonal antibody with mouse variable and human constant regions. It induces apoptosis and has antiproliferative effects. Ibritumomab tiuxetan (Zevalin) is composed of the monoclonal antibody ibritumomab, the linking chelator tiuxetan, and the radioisotope 90 yttrium [ ].
General adverse effects and adverse reactions
A wide range of adverse events has been reported. Most were hematological, thrombocytopenia being the most common, followed by a low hemoglobin and leukopenia. The most common non-hematological events were related to infusion and were similar to those reported with rituximab; they included weakness (54%), nausea (35%), chills (15%), and fever (21%) [ , ]. Infectious complications during treatment with ibritumomab are rare, pneumonia being the most common. There is no obvious hepatotoxicity.
You're Reading a Preview
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here